Alamar Biosciences, Inc. (ALMR) Stock Score, Valuation & Financial Research

Alamar Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALMR

Alamar Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 32.26. These figures are a research snapshot, not a buy or sell recommendation.

What Alamar Biosciences, Inc. does

Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Alamar Biosciences operates as a precision proteomics company that generates revenue primarily through the sale of its proprietary NULISA platform, which includes specialized instruments and associated consumables. The company also provides technical services and support to academic research institutions and biopharmaceutical companies to facilitate the early detection of diseases.

Products and services

  • The company offers the NULISA platform, which consists of analytical instruments and consumable assay kits designed for high-sensitivity protein detection and proteomic research.

Brands and product families

  • NULISA — The core proteomics platform brand for disease detection. Source

Customer types

Academic research institutions; Biopharmaceutical companies.

Suppliers, materials and equipment

  • Contract Manufacturing Services — The company utilizes third-party contract manufacturers for the production of its proprietary instruments and consumable components. Source

Business relationships and partnerships

  • Alzheimer’s Disease Data Initiative — A global partnership focused on advancing research and data sharing for Alzheimer's disease detection. Source
  • Gates Ventures — A strategic partnership supporting the expansion of global research initiatives and disease detection technologies. Source

Business strengths to evaluate

  • Proprietary NULISA platform technology Source

Business risks and research considerations

  • Dependence on third-party manufacturing and supply chain stability Source

Sources: Company research source · NULISA · Alzheimer’s Disease Data Initiative · Contract Manufacturing Services

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALMR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 32.26
Market capitalization:
2.24B (currency not supplied)
Revenue:
USD 74.21M
Net income:
USD -29.82M
Free cash flow:
USD -59.99M
Cash:
USD 132.97M
Total debt:
USD 51.41M
EPS:
USD -0.45

What stands out

  • Free cash flow is USD -59.99M, negative for the stored period.
  • The balance sheet shows USD 132.97M of cash versus USD 51.41M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -80.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -40.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 81.56M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALMR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ALMR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ALMR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ALMR to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of ALMR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research ALMR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.